Novadip Biosciences

Novadip Biosciences was founded in 2013 and is headquartered in Brussels. The company develops cell-based therapies for bone regeneration, targeting patients with significant bone defects from trauma, tumor removal, or congenital conditions. Novadip's approach uses adipose-derived stem cells to create bone substitute products.

The company raised $22M in a Series B round. It operates in the clinical-stage biotech space, where long development timelines are standard given regulatory requirements for cell-based therapies in both Europe and the US.